Targeting intracellular oncoproteins with antibody therapy or vaccination

Science Translational Medicine

Volumn 3, Issue 99, 2011, Pages

  Guo, Ke ^a   Li, Jie ^a   Tang, Jing Ping ^a   Tan, Cheng Peow Bobby ^a   Hong, Cheng William ^b   Al Aidaroos, Abdul Qader O ^a,c   Varghese, Leyon ^a   Huang, Caixia ^a   Zeng, Qi ^a,d  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B; ONCOPROTEIN; PHOSPHATASE OF REGENERATING LIVER 3 PROTEIN; POLYOMAVIRUS MIDDLE T PROTEIN; SC 53481; SC 9996; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TREATMENT FAILURE; FEMALE; IN VIVO STUDY; INTERNALIZATION; LYMPHOCYTE FUNCTION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REPRODUCIBILITY; WILD TYPE;

EID: 80052571556     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002296     Document Type: Article

References (30)

1. K. Imai, A. Takaoka, Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6, 714-727 (2006).
2. J. Cohen, A. Wilson, New challenges to Medicare beneficiary access to mAbs. MAbs 1, 56-66 (2009).
3. M. Baker, Upping the ante on antibodies. Nat. Biotechnol. 23, 1065-1072 (2005).
4. D. Alarcon-Segovia, A. Ruiz-Arguelles, E. Fishbein, Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors. Nature 271, 67-69 (1978).
5. A. Ruiz-Argüelles, D. Alarcón-Segovia, Penetration of autoantibodies into living cells, 2000. Isr. Med. Assoc. J. 3, 121-126 (2001).
6. K.-H. Sun, S.-J. Tang, M.-L. Lin, Y.-S. Wang, G.-H. Sun, W.-T. Liu, Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatology 40, 750-756 (2001).
7. D. C. Bessette, D. Qiu, C. J. Pallen, PRL PTPs: Mediators and markers of cancer progression. Cancer Metastasis Rev. 27, 231-252 (2008).
8. A. Q. Al-Aidaroos, Q. Zeng, PRL-3 phosphatase and cancer metastasis. J. Cell. Biochem. 111, 1087-1098 (2010).
9. S. M. Dilworth, Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nat. Rev. Cancer 2, 951-956 (2002).
10. C. T. Guy, R. D. Cardiff, W. J. Muller, Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12, 954-961 (1992).
11. S. Saha, A. Bardelli, P. Buckhaults, V. E. Velculescu, C. Rago, B. St Croix, K. E. Romans, M. A. Choti, C. Lengauer, K. W. Kinzler, B. Vogelstein, A phosphatase associated with metastasis of colorectal cancer. Science 294, 1343-1346 (2001).
12. R. H. Diamond, D. E. Cressman, T. M. Laz, C. S. Abrams, R. Taub, PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol. Cell. Biol. 14, 3752-3762 (1994).
13. Q. Zeng, W. Hong, Y. H. Tan, Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem. Biophys. Res. Comm. 244, 421-427 (1998).
14. A. Alonso, J. Sasin, N. Bottini, I. Friedberg, I. Friedberg, A. Osterman, A. Godzik, T. Hunter, J. Dixon, T. Mustelin, Protein tyrosine phosphatases in the human genome. Cell 117, 699-711 (2004).
15. Q. Zeng, X. Si, H. Horstmann, Y. Xu, W. Hong, C. J. Pallen, Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome. J. Biol. Chem. 275, 21444-21452 (2000).
16. J. A. Sager, S. Benvenuti, A. Bardelli, PRL-3: A phosphatase for metastasis? Cancer Biol. Ther. 3, 952-953 (2004).
17. H. Wang, L. A. Vardy, C. P. Tan, J. M. Loo, K. Guo, J. Li, S. G. Lim, J. Zhou, W. J. Chng, S. B. Ng, H. X. Li, Q. Zeng, PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell 18, 52-62 (2010).
18. Y. Ito, N. Spurr, B. E. Griffin, Middle T antigen as primary inducer of full expression of the phenotype of transformation by polyoma virus. J. Virol. 35, 219-232 (1980).
19. E. Gilboa, The promise of cancer vaccines. Nat. Rev. Cancer 4, 401-411 (2004).
20. K. Guo, J. P. Tang, C. P. Tan, H. Wang, Q. Zeng, Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol. Ther. 7, 750-757 (2008).
21. B. Weigelt, J. L. Peterse, L. J. Van't Veer, Breast cancer metastasis: Markers and models. Nat. Rev. Cancer 5, 591-602 (2005).
22. J. Li, K. Guo, V. W. Koh, J. P. Tang, B. Q. Gan, H. Shi, H. X. Li, Q. Zeng, Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases. Clin. Cancer Res. 11, 2195-2204 (2005).
23. Y. Shinkai, G. Rathbun, K. P. Lam, E. M. Oltz, V. Stewart, M. Mendelsohn, J. Charron, M. Datta, F. Young, A. M. Stall, F. W. Alt, RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68, 855-867 (1992).
24. T. Von der Weid, N. Honarvar, J. Langhorne, Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. J. Immunol. 156, 2510-2516 (1996).
25. R. A. Clynes, T. L. Towers, L. G. Presta, J. V. Ravetch, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443-446 (2000).
26. + dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J. Immunol. 185, 532-541 (2010).
27. W. Nickel, C. Rabouille, Mechanisms of regulated unconventional protein secretion. Nat. Rev. Mol. Cell Biol. 10, 148-155 (2009).
28. M. Bilous, M. Dowsett, W. Hanna, J. Isola, A. Lebeau, A. Moreno, F. Penault-Llorca, J. Rüschoff, G. Tomasic, M. Van de Vijver, Current perspectives on HER2 testing: A review of national testing guidelines. Mod. Pathol. 16, 173-182 (2003).
29. Y. Hüsemann, J. B. Geigl, F. Schubert, P. Musiani, M. Meyer, E. Burghart, G. Forni, R. Eils, T. Fehm, G. Riethmüller, C. A. Klein, Systemic spread is an early step in breast cancer. Cancer Cell 13, 58-68 (2008).
30. Acknowledgments: We are grateful to B. Vogelstein, D. Lane, W. Hong, C. Y. H. Tan, B. L. Tang, M. A. Lee, and W. N. Tay for their critical reading of the article. We thank J.-P. Abastado and P. J. Eun for helpful discussion. Funding: This work was supported by research grants from the Agency for Science, Technology and Research (A*STAR, Singapore) and by a Flagship award grant from Exploit Technologies Pte. Ltd. (amember of A*STAR). A.Q.O.A.-A. is a recipient of the A*STAR Graduate Scholarship. Author contributions: Q.Z. designed the experiments and wrote the paper. K.G., J.L., J.P.T., C.P.B.T., C.H., and L.V. performed the experiments. Q.Z., K.G., C.W.H., A.Q.O.A.-A., J.L., and J.P.T. analyzed the data. A.Q.O.A.-A., C.W.H., and L.V. carefully help inamending themanuscript. All authors approved the paper. Competing interests: Q.Z. is an inventor of the PCT International Patent Application No. PCT/SG2010/000449 titled "Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination" filed on November 30, 2010. The other authors declare that they have no competing interests.